Acutaas Chemicals' Q2 FY27 consolidated PAT jumps 71% YoY as margins expand to ~40%
PAT +71.38% YoY · revenue +42.69% · margins expanding · beat vs street
₹436.92 Cr
+42.69% YoY
₹123.14 Cr
+71.38% YoY
27.86%
+5.1pp YoY
₹15.29
Acutaas Chemicals (formerly Ami Organics) reported consolidated revenue of ₹436.92 Cr for Q2 FY27, up 42.7% year-on-year from ₹306.20 Cr and 32.5% sequentially from ₹329.67 Cr. Consolidated profit for the period (before minority interest) rose 71.4% YoY to ₹123.14 Cr from ₹71.86 Cr, with profit attributable to owners at ₹125.17 Cr (basic EPS ₹15.29 vs ₹8.82 a year ago) — profit growing well ahead of revenue YoY, the primary read on the quarter. No exceptional items appear in either the current or comparison periods, so this is a like-for-like beat, not a one-off.
Q2 FY-2027 vs prior quarters
The profit growth was driven by margin expansion rather than any one-time item: operating margin (EBITDA/revenue) expanded to roughly 40.3% from 31.1% a year ago and 34.3% last quarter, while net margin rose to 28.2% from 22.7% YoY. The expansion sits mainly on the cost-of-materials and other-expense lines relative to revenue, consistent with a richer product mix and operating leverage as volumes scale, rather than pricing or forex tailwinds.
The stock went into the print at ₹3,766, up 14.7% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
FY27 revenue growth of 25%, stable EBITDA margins vs FY26. Battery chemicals ramp over 3 years to 4,000 MT capacity utilization. CDMO targeting ₹1,000 Cr peak revenue. Capex ~₹90-95 Cr FY27 (electrolyte, maintenance, plus TBD R&D and land).
— This quarter: beat
Standalone and consolidated diverge materially on growth: standalone PAT of ₹135.74 Cr (EPS ₹16.58) grew 86.2% YoY, well ahead of the consolidated 71.4%, because consolidated numbers absorb drag from newer subsidiaries — notably Indichem Inc.'s South Korea semiconductor-materials plant (75%-owned via Acutaas Advance Material, ~₹200 Cr invested), inaugurated August 28, 2026 but still under trial runs at quarter-end. Against management's FY27 guidance of 25% revenue growth and stable margins versus FY26, H1 FY27 consolidated revenue of ₹766.59 Cr (+49.3% YoY) and the margin expansion both run well ahead — a clear beat on guidance. It also clears our pre-result preview, which had pencilled in revenue of ₹320-350 Cr, EBITDA margin of 33-35% and PAT of ₹100-120 Cr; the actual print topped every range.
W1
FY27 guidance is 25% revenue growth with stable margins vs FY26; H1 is already +49.3% YoY with OPM near 40% — watch for guidance reaffirmation or a raise on the call
W2
Indichem's South Korea plant remains under trial as of Sep 30, 2026 — watch for commercial ramp and its first contribution to consolidated revenue
W3
Enchem Ami Organics acquisition closed Oct 17, 2026 — watch for its first full-quarter contribution and integration costs in Q3 FY27
Acutaas Chemicals eyes margin durability amid CDMO expansion push
Q2 sets up as the first test of FY27's 25% growth guidance. Street consensus stands at ₹2,890–2,900 target, but execution on margins and the newly-completed Enchem acquisition will frame the narrative into year-end.
The setup: margin durability into CDMO scale
Q1 FY27 delivered a jolt — PAT up 70.4% YoY to ₹750 million, revenue +59.1% YoY, with EBITDA margins ballooning to 34.3%. That's the benchmark. Q2 will test whether those margins hold as the company integrates its newly-acquired Enchem subsidiary (closed Oct 17) and executes on the ₹212 crore capex envelope approved in August. The Street's baseline: 25% revenue growth for full-year FY27, which implies Q2 should land somewhere between Q1's outsized 59% and a more normalized run-rate. The CDMO franchise is the lever — the company targets ₹1,000 crore CDMO revenue by FY28, and Q2 will signal momentum into that milestone.
~₹320–350 Cr
40–50% YoY growth, tracking FY27 guidance at midpoint
~33–35%
Q1 set 34.3%; pricing power + scale should sustain it
~₹100–120 Cr
growing in-line with revenue given margin momentum; Enchem integration one-off items to flag
A strong Q2 print would show revenue in the ₹330–360 Cr range (45%+ YoY growth), EBITDA margins ≥34%, and a meaningful Enchem contribution (or clear pathway to it). A weak print would see revenue miss ₹300 Cr, margins slip below 32%, or acquisition-related costs mask underlying earnings. Watch for guidance updates on CDMO roadmap and full-year capex burn.
On track? The trajectory so far
Q1 FY27 established a strong run-in, with PAT growth of 70.4% and revenue +59.1% YoY — well ahead of the 25% FY27 guidance level. That's typical for H1, but it sets a bar. The bigger signal: EBITDA margins at 34.3% prove the mix is shifting favorably toward higher-margin CDMO and specialty products. Two caveats: Q1 benefited from full-quarter run-rate without seasonal headwinds, and the Enchem acquisition (effective Oct 17) doesn't yet show meaningful impact. Q2 will reveal whether the margin structure is structural or quarter-specific, and whether Enchem is accretive from day one or needs integration time.
Since last quarter: M&A, IP, and capex commitment
1 · Enchem Ami Organics acquisition (Oct 17)
Completed 100% acquisition of Enchem Ami Organics Private Limited (step-down subsidiary). This consolidates the wholly-owned subsidiary into a direct holding—likely a tax/simplification move, but watch Q2 for any synergy commentary or one-off costs.
2 · Semiconductor expansion: South Korea plant (Aug 28)
Subsidiary Indichem Inc. inaugurated a new semiconductor materials plant in Gongju, South Korea—built in 11 months. This unlocks the battery/semiconductor vertical (confirmed by MeitY ECMS approval in Aug). No revenue visibility into Q2, but signals long-term diversification away from pharma intermediates.
3 · Capex and pilot plant (Aug 22, Sep 4)
Board approved ₹212 crore capex program. Pilot plant inaugurated at Sachin Unit-1 for R&D trials. These are growth-stage investments; watch for capex burn rate in Q2 and any margin headwind from depreciation ramp.
4 · Patent and regulatory wins (Sep 10, Aug 18)
Granted 20-year process patent for 2,4-dimethylthiophenol and secured MeitY ECMS incentive approval. Routine de-risking of the product mix; positive signaling but not a Q2 earnings driver.
5 · FII inflow momentum (Q1 data)
FII shareholding rose from 19.48% (Q4 FY26) to 21.61% (Q1 FY27), a +2.13pp jump. DII flat, promoter stable at 32.66%. Inflows suggest institutional conviction on the CDMO thesis, but price (₹3,138 vs. ₹2,890 target) implies some rerating has already priced in.
What to watch on result day (Oct 27)
1 · EBITDA margin trend
Does 34%+ hold, or was Q1 a peak due to mix/seasonality? If margins slip below 33%, that signals pricing or mix pressure and could re-rate valuations downward.
2 · CDMO revenue & customer wins
Management's guidance to ₹1,000 crore CDMO by FY28 hinges on customer additions in H2. Q2 commentary on pipeline, ramp-up, and competitive wins will be the real headline.
3 · Enchem contribution & integration costs
Did the Oct 17 acquisition add material revenue in Oct–Sep period? Are there one-off restructuring costs that depress PAT? Clean execution here buys confidence into FY27.
4 · Full-year FY27 guidance reaffirmation
If management reaffirms 25% FY27 revenue growth and provides H2 visibility, the Street will treat it as a confidence signal. Any downgrade or silence will test sentiment at ₹3,138.
5 · Capex burn & semiconductor timeline
How much of the ₹212 crore capex has been deployed? When will semiconductor materials & battery chemicals turn cash flow positive? Patient money wants to see road-map credibility.
Acutaas Chemicals enters Q2 with momentum on its side—Q1 delivered rare 70% profit growth, and the CDMO transformation is real. But the stock is priced ahead of consensus targets, leaving little room for execution miss. Oct 27 will test margin durability after the Enchem consolidation, CDMO pace (the ₹1,000 crore FY28 target is credible but hungry), and whether the ₹212 crore capex gets deployed without significant near-term drag. The Street remains bullish, but execution on FY27 guidance—and candid commentary on H2 momentum—will determine whether the 16% discount to ATH (currently) narrows or widens into year-end.